lol on a 9 million dollar EV drug that’s been de risked early and exceeding expectations from early modelling and with a comparison company in AGN trading at a 70 million market cap which NYR is a superior drug. Interesting times but all time highs come phase 1 willl be taken out
Your looking at a 70-100 million market cap for where it’s at and the upside from there is exponential on its target market
Nyrada Talks PreClinical Success with 180 Markets, page-89
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
